Monoclonal Gammopathy of Neurological Significance (MGNS)

Article written and reviewed by Dr Luca Moretti

Monoclonal Gammopathy of Neurological Significance (MGNS) is a recently defined clinical entity identifying a group of peripheral neurologic disorders caused by monoclonal immunoglobulins or their fragments produced by a pathologic B-cell or plasma-cell clone, in the absence of diagnostic criteria for an overt hematologic malignancy such as multiple myeloma, Waldenstrom macroglobulinemia or aggressive lymphoma.

Analogous to Monoclonal Gammopathy of Renal Significance (MGRS), MGNS belongs to the spectrum of monoclonal gammopathies of clinical significance, in which the monoclonal protein acts as a direct pathogenic agent and causes tissue injury, in this case involving the peripheral nervous system, despite the absence of advanced hematologic malignancy or overt systemic involvement.

Clinically, MGNS encompasses several chronic neuropathies, particularly distal sensorimotor demyelinating neuropathy, typical of IgM anti-MAG gammopathies, sensory axonal neuropathy and multifocal polyneuropathies, as well as rarer and more specific forms associated with monoclonal IgG or IgA. The central pathogenetic mechanism is toxic or autoimmune activity of the monoclonal component against peripheral nerve constituents, including myelin or axonal antigens.

From an epidemiologic standpoint, the true prevalence of MGNS is uncertain because the nosologic definition is recent and because of frequent clinical overlap with other chronic neuropathies, especially in older people. The frequency of monoclonal gammopathies rises with age and their presence in a patient with neuropathy may therefore be incidental; causality is more plausible in typical IgM phenotypes, particularly anti-MAG. Incidence is greatest between the sixth and eighth decades of life, with a slight male predominance.

Diagnosis is often delayed because symptoms progress slowly, the clinical picture is nonspecific and the monoclonal component is small. Early recognition is nevertheless fundamental: only identification of a causal relationship between the neuropathy and monoclonal component allows targeted treatment and reduction of further disability in treatable phenotypes.

Etiology, pathogenesis and pathophysiology

MGNS requires causal attribution of the neuropathy to a monoclonal immunoglobulin; this relationship is best established for certain IgM phenotypes, whereas coexistence is often noncausal in IgG or IgA gammopathies. The underlying clone may be B-cell or plasma-cell in origin, without diagnostic criteria for multiple myeloma, Waldenstrom macroglobulinemia or another overt hematologic neoplasm. In many cases, MGNS arises from monoclonal gammopathy of undetermined significance (MGUS), but it may also occur with indolent lymphoproliferative disorders or plasma-cell dyscrasias that have not progressed to an advanced neoplastic stage.
In the most typical form, neuropathy is associated with IgM immunoglobulins with autoantibody activity against myelin-associated glycoprotein (anti-MAG), but variants associated with monoclonal IgG or IgA and different mechanisms of injury have also been described.

No specific risk factors for MGNS have been defined. Advanced age increases the frequency of both monoclonal gammopathies and neuropathies and therefore also increases the likelihood of coincidental coexistence. Neuropathy develops in only a minority of people with MGUS or other gammopathies, however, suggesting a central role for specific autoimmune or toxic properties of the immunoglobulins produced.

From a pathogenetic standpoint, neurologic injury in MGNS is mainly related to two mechanisms:

• Autoantibody activity: monoclonal immunoglobulins, especially IgM, may recognize antigens in peripheral nerve myelin such as myelin-associated glycoprotein (MAG), gangliosides such as GM1 and GD1b or other components of the node of Ranvier. Binding to myelin targets activates complement and induces chronic demyelinating lesions with disruption and loss of the myelin sheath.
• Specific mechanisms in non-IgM gammopathies: in neuropathies associated with IgG or IgA, a direct causal relationship cannot be assumed without identifying a defined entity. In AL amyloidosis, injury may be related to fibril deposition and light-chain toxicity; in POEMS syndrome, neuropathy is associated with cytokine dysregulation, particularly VEGF, rather than a demonstrated direct effect of the paraprotein.

Some variants are characterized by immune-complex formation with deposition in vessels supplying peripheral nerves, as in monoclonal immunoglobulin-associated vasculitis, triggering inflammatory and ischemic mechanisms that contribute to neurologic dysfunction.

At the pathophysiologic level, injury depends on the monoclonal protein and the clinical entity. In IgM anti-MAG neuropathy, the pattern is typically distal, symmetric and slowly progressive demyelination with marked prolongation of distal latencies; conduction blocks are unusual. Axonal forms predominantly involve the axons.
Involvement may be symmetric and distal, which is more typical, or may have a multifocal and progressive pattern that can worsen rapidly, particularly in deposition or vasculitic variants.

The severity and speed of progression depend on several factors, including titer and affinity of the monoclonal component, structural properties of the immunoglobulin, individual genetic factors and coexistence of other predisposing conditions such as diabetes or vascular disease. Progression is slow and insidious in many patients, but rapidly evolving forms may lead to severe disability within a short period.

Overall, MGNS represents a paradigmatic monoclonal-immunoglobulin-mediated autoimmune disease in which early recognition of the pathogenetic mechanism allows specific therapeutic strategies and may prevent irreversible deterioration of neurologic function.

Clinical manifestations

The clinical manifestations of MGNS are extremely heterogeneous and depend on both the isotype of the monoclonal component and the specific pathogenetic mechanism. In general, the presentation is that of a progressive chronic peripheral neuropathy, often insidious and slowly evolving, which may involve different parts of the peripheral nervous system and produce different patterns according to the immunoglobulin and antigenic targets involved.

In the most typical form, associated with monoclonal IgM anti-MAG, patients develop a distal sensorimotor demyelinating neuropathy characterized by paresthesias, hypoesthesia and numbness of the extremities, especially the feet and hands, symmetric distal weakness, loss of deep tendon reflexes and sensory ataxia. Sensory disturbances predominate, including tingling, reduced vibration sense and impaired proprioception, which may cause gait instability and falls. Motor weakness is usually mild or moderate and predominantly affects distal lower-limb muscles and, in advanced cases, the upper limbs. Progression is slow but may lead to substantial functional disability if untreated.

In cases associated with monoclonal IgG or IgA, neuropathy often has an axonal predominance, with purely sensory or sensorimotor involvement. Manifestations include distal hypoesthesia, neuropathic pain, loss of pain and temperature sensation and variable muscle weakness. The picture may resemble small-fiber neuropathy with burning pain and dysesthesia or may present as a chronic polyradiculoneuropathy.

In some forms, especially with vasculitic activity or immune-complex deposition, multifocal polyneuropathy or mononeuritis multiplex may occur, with acute or subacute onset, asymmetric motor and sensory deficits, severe pain and rapid progression, often associated with systemic signs such as fever, rash, arthralgia, Raynaud syndrome and peripheral purpura. These patterns are more frequent in monoclonal cryoglobulinemias or gammopathies with complex autoantibody activity.

Neurologic examination typically reveals areflexia, stocking-and-glove hypoesthesia, reduced vibration and proprioceptive sensation, distal motor deficits more evident in the lower limbs, muscle wasting in advanced disease and, sometimes, joint deformities related to postural instability. In small-fiber neuropathy, neuropathic pain may predominate and may be associated with sweating disturbances or peripheral vasomotor abnormalities.

Clinical progression is generally slow and gradual in IgM anti-MAG demyelinating forms, but may be subacute or rapidly progressive in deposition or vasculitic variants. Without treatment, the condition may evolve toward progressive disability, loss of independent ambulation, frequent falls and worsening quality of life. Cranial nerve involvement and respiratory impairment are rare but possible in more aggressive forms.

In summary, the clinical presentation of MGNS is dominated by distal sensory disturbances, muscle weakness, loss of reflexes and neuropathic pain. Heterogeneity of presentation, frequent insidious onset and overlap with other chronic neuropathies often delay diagnosis. Careful clinical evaluation, targeted testing for a monoclonal component and correlation with neurophysiologic findings are essential for early recognition and appropriate treatment.

Investigations and diagnosis

The diagnosis of MGNS is complex and requires integration of clinical, laboratory, neurophysiologic, immunochemical and histopathologic data. Suspicion should arise in patients with chronic peripheral neuropathy or slowly progressive polyneuropathy, especially in adults or older individuals, in whom a serum or urinary monoclonal component is found, even at low concentration, and an overt hematologic malignancy has been excluded.

The initial evaluation includes routine and specific laboratory tests: complete blood count, immunoglobulin profile (IgG, IgA, IgM), serum and urine electrophoresis with immunofixation, free light-chain quantification and kappa/lambda ratio, markers of organ damage, testing for viral infections such as HIV, HCV and HBV, and investigation of other causes of neuropathy.
Identification of the monoclonal component may require highly sensitive methods because the concentration may be extremely low. In the presence of monoclonal IgM, testing for anti-MAG autoantibodies, anti-ganglioside antibodies or other neural autoantigens is essential.

Neurophysiologic testing is fundamental for characterizing the neuropathy. In IgM anti-MAG forms it typically shows symmetric distal demyelination, markedly prolonged distal latencies and a low terminal latency index, with conduction blocks being uncommon; axonal forms instead show reduced potential amplitudes. The pattern guides the differential diagnosis with CIDP and other neuropathies.

Cerebrospinal fluid analysis, when indicated, may show albuminocytologic dissociation; significant pleocytosis should prompt investigation of alternative diagnoses. Oligoclonal bands or monoclonal immunoglobulins in cerebrospinal fluid are not diagnostic criteria for MGNS. Nerve biopsy is reserved for selected cases, particularly when vasculitis, amyloidosis or infiltration is suspected.

The central element of the diagnostic pathway is demonstrating a causal relationship between the neuropathy and the monoclonal component. Only a minority of individuals with monoclonal gammopathy develop clinically relevant neuropathy, so clinical suspicion must be supported by immunopathologic evidence and exclusion of other causes.

The diagnosis of MGNS is a diagnosis of exclusion and requires:

• clinical and electrophysiologic characterization of the neuropathy;
• identification and typing of the monoclonal gammopathy;
• exclusion of common causes and defined entities, including AL amyloidosis, POEMS, cryoglobulinemia and neoplastic infiltration;
• assessment of causal plausibility, which is higher in distal IgM demyelinating neuropathies with anti-MAG antibodies and more uncertain in IgG/IgA gammopathies.

High-titer anti-MAG autoantibodies, together with a compatible clinical and electrophysiologic phenotype, strongly support causality in IgM forms. In the absence of specific markers, diagnosis remains probabilistic and is based on exclusion of other causes and clinical-biologic consistency, not on therapeutic response as a diagnostic criterion.

Complementary investigations include hematologic assessment with bone marrow aspiration and biopsy and flow cytometry, supportive imaging such as MRI of marrow and nerves and PET/CT when indicated, genetic testing in suspected familial or rare variants, and monitoring of progression markers such as increase in the monoclonal component or worsening neurophysiology.

Early and accurate diagnosis of MGNS allows prompt referral for targeted treatment, helping prevent progression of neurologic disability and significantly improving functional prognosis.

Treatment and prognosis

Treatment of MGNS depends on the defined causal entity and severity of the neuropathy. Clinically significant IgM anti-MAG forms may warrant therapy directed at the B-cell clone, whereas IgG or IgA neuropathies with a CIDP-like phenotype are treated with an immunomodulatory approach similar to CIDP after AL amyloidosis, POEMS and other specific causes have been excluded.

In IgM anti-MAG-associated forms, the most typical and best characterized variant, treatment is generally reserved for patients with significant or progressive disability and should target the underlying B-cell clone. Rituximab, alone or in selected combinations, has inconsistent evidence and does not guarantee a neurologic response; immunochemotherapy is not a universal first-line strategy. In patients with a Waldenstrom macroglobulinemia phenotype or MYD88 L265P mutation, BTK inhibitors such as ibrutinib may be considered in selected settings according to the benefit-risk balance.

Neuropathies associated with monoclonal IgG or IgA are often of uncertain causality. After excluding AL amyloidosis, POEMS and other defined entities, a phenotype compatible with CIDP is treated with standard CIDP therapies such as IVIG, corticosteroids or plasma exchange. Plasma-cell-directed therapy is reserved for conditions in which a clonal relationship is established; potentially neurotoxic agents such as bortezomib are not a generic treatment choice.

Plasma exchange and IVIG generally do not provide durable benefit in anti-MAG neuropathy; they may have a limited and transient role in selected phenotypes or alternative diagnoses, not as general therapy for MGNS.

Intravenous immunoglobulin (IVIG) may be effective in IgG or IgA neuropathies with a CIDP-like phenotype; in IgM anti-MAG neuropathy the benefit is generally absent, modest or transient and does not represent a standard maintenance strategy.

Supportive therapies are fundamental to quality of life and include neuromotor rehabilitation, physiotherapy aimed at preventing disability, treatment of neuropathic pain with antiepileptics, tricyclic antidepressants, duloxetine or gabapentinoids, management of autonomic complications and nutritional monitoring. Severe cases require multidisciplinary support from neurologists, hematologists, physiatrists and pain specialists.

Functional prognosis depends on the neuropathic phenotype, rate of progression, baseline disability and response to treatment of the specific causal entity. IgM anti-MAG forms tend to progress slowly but may lead to severe disability if untreated. A favorable immunologic and clinical response is associated with stabilization and, in a substantial proportion of cases, partial functional recovery. Forms associated with IgG/IgA or deposition/vasculitis may be more aggressive and require more intensive and prolonged treatment.

Follow-up requires periodic clinical monitoring, measurement of the monoclonal component and autoantibodies, serial neurophysiologic assessment and surveillance for possible progression of the gammopathy to an overt hematologic malignancy. Relapse or clinical worsening may require treatment intensification or innovative agents.

Overall, MGNS management requires an individualized, timely and multidisciplinary approach aimed at limiting progression of neurologic disability, reducing symptom burden and improving quality of life in patients with this form of immune-mediated neuropathy.

Complications

The complications of MGNS are central determinants of quality of life and functional prognosis. They result from progression of chronic peripheral neuropathy, direct effects of monoclonal immunoglobulins and consequences of immunosuppressive or antineoplastic treatment.

The main complication is progressive neurologic disability. Without treatment or in treatment-resistant disease, neuropathy may progress to substantial loss of distal muscle strength, severe sensory deficits, ataxia and inability to walk independently. Functional impairment may extend to daily activities such as dressing, eating and personal hygiene and may lead to bed confinement in the most severe cases.

Chronic neuropathic pain, often resistant to common analgesics, is a frequent and difficult-to-treat complication that worsens sleep quality, mood and ability to work. It may be associated with dysesthesia, allodynia and abnormalities of thermal and pain sensation.

Marked autonomic symptoms such as orthostatic hypotension or gastrointestinal or sphincter disturbances are not typical of anti-MAG neuropathy and should prompt investigation for AL amyloidosis, POEMS, diabetic neuropathy or other causes; such manifestations may occur in specific underlying entities rather than as a general MGNS complication.

Muscle weakness and distal muscle wasting, together with areflexia, expose patients to an increased risk of traumatic falls, fractures and joint injuries such as subluxations and musculoskeletal deformities secondary to instability and ataxia.

Psychosocial complications are important and include anxiety, depression, social isolation and loss of independence, with increased risk of secondary depressive syndromes and impaired quality of life. The effects on family and working life are often underestimated and require dedicated support.

Iatrogenic complications of immunosuppressive or antineoplastic treatment include opportunistic bacterial, viral and fungal infections, cytopenias such as anemia, neutropenia and thrombocytopenia, hepatic, renal or cardiac organ toxicity, allergic reactions and, with prolonged therapies, a theoretical risk of secondary neoplasia.

In patients treated with rituximab or other anti-CD20 agents, the risk of hepatitis B reactivation, severe viral infections and persistent hypogammaglobulinemia must be carefully monitored and managed with prophylaxis and laboratory surveillance.

Although rare, progression of the monoclonal gammopathy to an overt hematologic malignancy, such as Waldenstrom macroglobulinemia, multiple myeloma or B-cell lymphoma, is an important complication and requires long-term hematologic monitoring.

In conclusion, management of MGNS complications is an integral part of care: fall prevention, early treatment of neuropathic pain, psychological and social support, monitoring for infection and organ dysfunction and hematologic surveillance are essential to improve functional prognosis, preserve residual neurologic function and optimize quality of life.

References
1. Castillo JJ et al. The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance. American Journal of Hematology. 96, 7, 2021, 846-853.
2. Khwaja J et al. IgM monoclonal gammopathies of clinical significance: diagnosis and management. Haematologica. 107, 9, 2022, 2037-2050.
3. Beydoun SR, Darki A. Paraproteinemic Neuropathies. Continuum. 29, 5, 2023, 1492-1513.
4. Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management. Mayo Clinic Proceedings. 92, 5, 2017, 838-850.
5. Dalakas MC et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Annals of Neurology. 65, 3, 2009, 286-293.
6. Léger JM et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 80, 24, 2013, 2217-2225.
7. D’Sa S et al. Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. British Journal of Haematology. 176, 5, 2017, 728-742.
8. Nobile-Orazio E et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain. 123, Pt 4, 2000, 710-717.
9. Gruson B et al. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. Journal of the Peripheral Nervous System. 16, 3, 2011, 180-185.
10. Cibeira MT et al. Neurological manifestations of MGUS. Hematology. American Society of Hematology Education Program. 2024, 1, 2024, 499-504.